Valuation Abbott Laboratories Deutsche Boerse AG
Stocks
ABL0
CA0028221046
Medical Equipment, Supplies & Distribution
|
Delayed
Deutsche Boerse AG
07:50:13 07/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 10.70 EUR | -1.83% |
|
-1.83% | -20.15% |
| 01:14pm | Barclays Initiates Coverage on Abbott Laboratories With Overweight Rating, $120 Price Target | MT |
| 10-05 | Abbott Laboratories Receives FDA Approval for New CardioMEMS HF System capabilities | CI |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 169,854 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -22.03% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 193,793 | 190,812 | 187,121 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -12.81% | -1.54% | -1.93% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 28.7x | 22.3x | 19.5x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.55x | 3.4x | 3.22x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -3.51x | 0.8x | 1.4x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.38x | 3.12x | 2.92x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.86x | 3.5x | 3.21x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 14.9x | 13.2x | 11.8x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 16.5x | 14.7x | 13.1x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.7x | 21.4x | 19.5x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.89% | 4.68% | 5.13% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.57 | 2.741 | 2.898 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.62% | 2.79% | 2.95% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.416 | 4.402 | 5.024 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 75.2% | 62.3% | 57.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,201 | 54,527 | 58,253 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,982 | 14,468 | 15,892 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,720 | 13,022 | 14,320 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,212 | 7,894 | 8,780 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 98.16 | 98.16 | 98.16 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 28.74x | 3.86x | 14.93x | 2.62% | 170B | |
| 18.62x | 3.4x | 12.17x | 3.23% | 111B | |
| 21.64x | 4.26x | 14.86x | 1.29% | 107B | |
| 25.96x | 2.55x | 10.26x | 2.76% | 75.95B | |
| 17.32x | 0.2x | 12.68x | 0.75% | 60.37B | |
| 30.98x | 7.66x | 19.84x | 1.29% | 53.53B | |
| 34.74x | 3.37x | 11.55x | 2.18% | 49.11B | |
| 34.91x | 8.68x | 24.41x | -.--% | 40.6B | |
| 33.51x | 5.87x | 18.42x | -.--% | 31.47B | |
| Average | 27.38x | 4.43x | 15.46x | 1.57% | 77.67B | |
| Weighted average by Cap. | 25.92x | 4.02x | 14.62x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABL0 Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
